JP2017524704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524704A5 JP2017524704A5 JP2017504421A JP2017504421A JP2017524704A5 JP 2017524704 A5 JP2017524704 A5 JP 2017524704A5 JP 2017504421 A JP2017504421 A JP 2017504421A JP 2017504421 A JP2017504421 A JP 2017504421A JP 2017524704 A5 JP2017524704 A5 JP 2017524704A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- substituted
- acceptable salt
- compound according
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RHASGUGQMCVYMQ-UHFFFAOYSA-N N#Cc(cc1)ccc1-c1cnccc1SCC1(CC(O)=O)CC1 Chemical compound N#Cc(cc1)ccc1-c1cnccc1SCC1(CC(O)=O)CC1 RHASGUGQMCVYMQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410398333.4 | 2014-08-13 | ||
| CN201410398333.4A CN105439946B (zh) | 2014-08-13 | 2014-08-13 | 羧酸化合物及其制备方法和用途 |
| PCT/CN2015/086605 WO2016023460A1 (zh) | 2014-08-13 | 2015-08-11 | 羧酸化合物及其制备方法和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524704A JP2017524704A (ja) | 2017-08-31 |
| JP2017524704A5 true JP2017524704A5 (enExample) | 2018-09-13 |
| JP6568929B2 JP6568929B2 (ja) | 2019-08-28 |
Family
ID=55303876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504421A Active JP6568929B2 (ja) | 2014-08-13 | 2015-08-11 | カルボン酸化合物、その製造方法および使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9809580B2 (enExample) |
| EP (1) | EP3181557B1 (enExample) |
| JP (1) | JP6568929B2 (enExample) |
| KR (1) | KR102474640B1 (enExample) |
| CN (2) | CN105439946B (enExample) |
| AU (1) | AU2015303597B2 (enExample) |
| CA (1) | CA2956045C (enExample) |
| ES (1) | ES2942259T3 (enExample) |
| IL (1) | IL250524B (enExample) |
| NZ (1) | NZ729037A (enExample) |
| WO (1) | WO2016023460A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105439946B (zh) * | 2014-08-13 | 2018-02-02 | 益方生物科技（上海）有限公司 | 羧酸化合物及其制备方法和用途 |
| JP6898330B2 (ja) * | 2015-12-28 | 2021-07-07 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | インドリジン誘導体、組成物、及び使用方法 |
| CN105884807A (zh) * | 2016-04-26 | 2016-08-24 | 昆药集团股份有限公司 | 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法 |
| CN106748987B (zh) * | 2016-11-18 | 2019-05-31 | 昆药集团股份有限公司 | 2-((3-(4-氰基萘-1-基)吡啶-4-基)硫基)-2-甲基丙酸钠盐的晶型 |
| KR20200064101A (ko) * | 2017-10-04 | 2020-06-05 | 니뽄 다바코 산교 가부시키가이샤 | 질소 함유 헤테로아릴 화합물 및 그의 의약 용도 |
| CN108084153A (zh) * | 2017-12-20 | 2018-05-29 | 广东赛烽医药科技有限公司 | 吡啶基硫代乙酸化合物、组合物及其应用 |
| CN108069940B (zh) * | 2017-12-20 | 2021-04-30 | 广东赛烽医药科技有限公司 | 硫代乙酸化合物、组合物及其应用 |
| CN108440397B (zh) * | 2018-03-06 | 2020-06-05 | 南方医科大学 | 3-(萘-1-甲基取代)吡啶衍生物及其合成方法和应用 |
| WO2019183835A1 (en) * | 2018-03-28 | 2019-10-03 | Inventisbio Shanghai Ltd. | Novel salt forms of urat-1 inhibitors |
| CN108484494B (zh) * | 2018-06-15 | 2021-07-30 | 沈阳药科大学 | 2-氧代-1,2-二氢吡啶-4-甲酸类化合物 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN113493407B (zh) * | 2020-04-03 | 2025-01-28 | 中国医学科学院药物研究所 | 一种吡啶类化合物及其制法和药物用途 |
| EP4301749A1 (en) * | 2021-03-01 | 2024-01-10 | Orion Corporation | Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor |
| AR124985A1 (es) * | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| CN113979931B (zh) * | 2021-10-08 | 2023-06-13 | 南方医科大学 | 一种吡啶3-胺衍生物及其制备方法和应用 |
| CN116715633B (zh) * | 2022-04-27 | 2025-08-12 | 杭州新元素药业股份有限公司 | 可用于降尿酸的化合物 |
| AU2024346175A1 (en) * | 2023-09-19 | 2026-04-09 | Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd. | Six-membered and five-membered fused ring derivative, and preparation method therefor and use thereof |
| WO2025060752A1 (zh) * | 2023-09-19 | 2025-03-27 | 湘北威尔曼制药股份有限公司 | 一种硫醚衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19541146A1 (de) * | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| FR2903984B1 (fr) * | 2006-07-24 | 2008-10-03 | Genfit Sa | Derives d'imidazolones substitues, preparation et utilisations |
| US8729095B2 (en) * | 2009-08-28 | 2014-05-20 | Daiichi Sankyo Company, Limited | 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases |
| AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| BR112012032193A2 (pt) * | 2010-06-16 | 2019-09-24 | Ardea Biosciences Inc | composto, composiçoes e métodos de uso de feniltioacetato |
| EP3501520A1 (en) * | 2011-11-03 | 2019-06-26 | Ardea Biosciences, Inc. | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same |
| US20150291514A1 (en) * | 2012-01-04 | 2015-10-15 | Pfizer Limted | N-Aminosulfonyl Benzamides |
| WO2013158422A1 (en) * | 2012-04-17 | 2013-10-24 | E. I. Du Pont De Nemours And Company | Heterocyclic compounds for controlling invertebrate pests |
| CN105439946B (zh) * | 2014-08-13 | 2018-02-02 | 益方生物科技（上海）有限公司 | 羧酸化合物及其制备方法和用途 |
-
2014
- 2014-08-13 CN CN201410398333.4A patent/CN105439946B/zh active Active
-
2015
- 2015-08-11 AU AU2015303597A patent/AU2015303597B2/en active Active
- 2015-08-11 JP JP2017504421A patent/JP6568929B2/ja active Active
- 2015-08-11 CA CA2956045A patent/CA2956045C/en active Active
- 2015-08-11 ES ES15831615T patent/ES2942259T3/es active Active
- 2015-08-11 KR KR1020177006929A patent/KR102474640B1/ko active Active
- 2015-08-11 NZ NZ729037A patent/NZ729037A/en unknown
- 2015-08-11 CN CN201580043042.6A patent/CN106573908B/zh active Active
- 2015-08-11 WO PCT/CN2015/086605 patent/WO2016023460A1/zh not_active Ceased
- 2015-08-11 US US15/501,387 patent/US9809580B2/en active Active
- 2015-08-11 EP EP15831615.8A patent/EP3181557B1/en active Active
-
2017
- 2017-02-09 IL IL250524A patent/IL250524B/en active IP Right Grant
- 2017-10-03 US US15/723,785 patent/US9856239B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524704A5 (enExample) | ||
| JP2012527475A5 (enExample) | ||
| MX2022014312A (es) | Inhibidores de sarcomero cardiaco. | |
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| HRP20140391T1 (hr) | Spojevi i pripravci tioacetata, te postupci uporabe | |
| EP4660303A3 (en) | Pcsk9 antagonist compounds | |
| JP2016518437A5 (enExample) | ||
| RU2013119129A (ru) | Органические соединения | |
| WO2010059239A3 (en) | Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders | |
| JP2016528276A (ja) | プラーク退縮を促進するための組成物及び治療法 | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| RU2011143741A (ru) | Производное индолизина и его применение в медицинских целях | |
| JP2017523219A5 (enExample) | ||
| JP2016540759A5 (enExample) | ||
| RU2003136077A (ru) | Применение соединений, обладающих совместной ингибирующей активностью в отношении nep (нейтральная эндопептидаза) и мр (металлопротеаза), для приготовления лекарственных средств | |
| JP2012526769A5 (enExample) | ||
| JOP20240120A1 (ar) | مشتقات 4-فينيل-2-(1h-3،2،1-تريازول-4-يل) بيبيريدين-4-أول كمثبطات لـ apol1 وطرق استخدامها | |
| JP2017531673A5 (enExample) | ||
| JPWO2023195529A5 (enExample) | ||
| CY1124383T1 (el) | Προληψη ή αγωγη παθησης ουρικου οξεος ή ποδαγρας | |
| JP2021042207A (ja) | トロンボキサン受容体アンタゴニスト | |
| JP2019065009A5 (enExample) | ||
| JP2017515899A5 (enExample) | ||
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| JP2019507167A5 (enExample) |